spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Pulmonary Embolism 

 HSMN NewsFeed - 17 Jan 2025
FDA Approves LUMAKRAS(R) (Sotorasib) in Combination with Vectibix(R) (Panitumumab) for Chemorefractory KRAS G12C-Mutated Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Sep 2024
Penumbra Receives CE Mark for Computer Assisted Vacuum Thrombectomy Technologies - Lightning Flash(TM) 2.0 and Lightning Bolt(TM) 7 - in Europe
Devices Interventional Regulatory
 HSMN NewsFeed - 20 Aug 2024
RYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Jul 2022
Anthos Therapeutics Announces that Abelacimab has Received FDA Fast Track Designation for the Treatment of Thrombosis Associated with Cancer
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Jun 2022
Cordis-X Makes Strategic Investment in Adient Medical, Developer of First Fully Absorbable Inferior Vena Cava (IVC) Filter
Devices Venture Capital
 HSMN NewsFeed - 10 May 2022
Magneto Thrombectomy Solutions Announces Successful First-in-Human Results for Treatment of Pulmonary Embolism (PE)
Devices Interventional
 HSMN NewsFeed - 14 Apr 2022
NCCN Guidelines(R) Recommend VONJO(TM) (pacritinib) for the Treatment of Myeloproliferative Neoplasms
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Oct 2021
FDA Approves Verzenio(R) (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Sep 2021
OLUMIANT(R) Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata
Biopharmaceuticals
 HSMN NewsFeed - 16 Sep 2021
LUMAKRAS(TM) (Sotorasib) Combined With Vectibix(R) (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Sep 2021
CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR(TM) Antithrombotic Removal System During Urgent Cardiothoracic Surgery
Devices Surgery FDA
 HSMN NewsFeed - 24 Aug 2021
European Commission Approves RINVOQ(R) (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 12 Aug 2021
Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents' DrugSorb-ATR(TM) Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardiothoracic Surgery
Devices FDA
 HSMN NewsFeed - 4 Aug 2021
Boston Scientific Initiates Randomized Controlled Trial for the EkoSonic(TM) Endovascular System
Devices Interventional
 HSMN NewsFeed - 3 Aug 2021
Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation
Biopharmaceuticals
 HSMN NewsFeed - 20 Apr 2021
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
Biopharmaceuticals
 HSMN NewsFeed - 15 Apr 2021
Valeo Pharma Announces Commercial Launch of Redesca(TM) and Redesca HP(TM)
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 8 Apr 2021
Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients
Biopharmaceuticals
 HSMN NewsFeed - 16 Mar 2021
Imbio Receives FDA 510(k) Clearance for New Cardiothoracic Imaging Algorithm
Devices Cardiology Radiology FDA
 HSMN NewsFeed - 24 Feb 2021
Clarus Therapeutics Appoints Richard 'Ric' Peterson as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Dec 2020
Medtronic's OsteoCool(TM) Procedure Shows Significant, Swift Pain Relief and Sustained Improvement for Cancer Patients
Devices Interventional Oncology
 HSMN NewsFeed - 11 Dec 2020
CHMP Recommends the Approvals of RINVOQ(TM) (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Dec 2020
Valeo Pharma Announces Health Canada Approval for Redesca(TM) and Redesca Hp(TM)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 10 Nov 2020
Penumbra Announces Partnership with RapidAI to Enable Faster Clinical Decision-Making for Pulmonary Embolism
Devices
 HSMN NewsFeed - 18 Sep 2020
CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 14 May 2020
U.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa(R) for Third Year
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 12 May 2020
CytoSorb(R) is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery
Devices Regulatory
 HSMN NewsFeed - 6 May 2020
FDA Clears New Mechanical Thrombectomy Platform
Devices Interventional FDA
 HSMN NewsFeed - 7 Apr 2020
Portola Pharmaceuticals Announces the Establishment of a Permanent J-code for Andexxa by the Centers for Medicare & Medicaid Services, Effective July 1, 2020
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 16 Mar 2020
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Mar 2020
New Data Demonstrates Andexxa(R) Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors
Biopharmaceuticals
 HSMN NewsFeed - 22 Jan 2020
Argon Medical Announces the Commercial Launch of Two Inferior Vena Cava Filter Retrieval Kits
Devices Interventional Product Launch
 HSMN NewsFeed - 19 Aug 2019
Boston Scientific Closes Acquisition of BTG plc.
Devices Interventional Oncology Mergers & Acquisitions
 HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jul 2019
Lilly's Verzenio(R) (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jun 2019
AI for C-Spine Fractures: Aidoc Sets the Pace With 3rd FDA Clearance in 9 Months
Devices Radiology Neurosurgery Orthopaedic FDA
 HSMN NewsFeed - 18 Dec 2018
Lilly Announces Publication of Analyses Showing Benefit of the Addition of Verzenio(R) (Abemaciclib) in Multiple Subgroups of Patients with Advanced Breast Cancer Identified as Having a More Concerning Prognosis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Dec 2018
FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Nov 2018
Boston Scientific Announces Recommended Offer to Acquire BTG plc.
Devices Interventional Oncology Mergers & Acquisitions
 HSMN NewsFeed - 23 Oct 2018
Duchesnay Inc. Announces Submission of Supplemental New Drug Application (sNDA) for Osphena(R) (ospemifene) to U.S. FDA Seeking Approval for the Treatment of Vaginal Dryness, a Symptom of Vulvar and Vaginal Atrophy (VVA) Due to Menopause
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Oct 2018
FDA Approves KYPROLIS(R) (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Aug 2018
Daiichi Sankyo Presents First Snapshot Analyses from Global ETNA-AF Programme of Oral, Once-daily LIXIANA(R) (edoxaban) in Patients with Nonvalvular Atrial Fibrillation in Routine Clinical Practice
Biopharmaceuticals
 HSMN NewsFeed - 27 Aug 2018
Janssen Announces Results from MARINER and COMMANDER HF Studies
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 13 Aug 2018
New Analysis Identifies Patient Populations With Cancer-associated VTE Who Could Benefit From Treatment With Oral, Once-daily LIXIANA(R) (edoxaban)
Biopharmaceuticals
 HSMN NewsFeed - 7 Aug 2018
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI(TM) in combination with MEKTOVI(R) and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Jul 2018
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI(TM) (encorafenib) in Combination with MEKTOVI(R) (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jun 2018
Medtronic Announces Second Bone Cement Solution Indicated for Treating Sacral Fractures
Devices Interventional Radiology Orthopaedic FDA
 HSMN NewsFeed - 11 Jun 2018
Roche introduces first self-testing device for Warfarin monitoring with built in Bluetooth(R) technology
Devices Monitoring Product Launch
 HSMN NewsFeed - 6 Apr 2018
Impax Launches a Generic Version of Estrace(R) Cream (estradiol vaginal cream, USP, 0.01%)
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 30 Oct 2017
FDA Approves New 10 mg Dosing for XARELTO(R) (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Oct 2017
FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio(TM) (abemaciclib) as Initial Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Sep 2017
ManaMed Inc. Introduces PlasmaFlow, The World's First FDA-Approved Digital and Tubeless Deep Vein Thrombosis Prevention Device
Devices Product Launch
 HSMN NewsFeed - 17 Jul 2017
CHMP Issues a Positive Opinion for Daiichi Sankyo's Once-Daily LIXIANA(R) (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Apr 2017
Inari Medical Announces First Patient Treated with the ClotTriever(TM) Thrombectomy System
Devices Interventional Product Launch
 HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Jan 2017
First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS(R) system
Devices Product Launch
 HSMN NewsFeed - 15 Nov 2016
Portola Pharmaceuticals Announces Three Phase 3 APEX Substudy Results Showing Further Benefits of Treating Acute Medically Ill Patients with Extended-Duration Betrixaban
Biopharmaceuticals
 HSMN NewsFeed - 11 Nov 2016
Bristol-Myers Squibb’s Opdivo(R) (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Nov 2016
IBRANCE(R) (palbociclib) Receives Approval in European Union for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Oct 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Oct 2016
First Positive Phase 3 Results in Adjuvant Setting for Renal Cell Carcinoma Show SUTENT(R) (sunitinib) Extended Disease Free Survival After Surgical Removal
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Sep 2016
European Commission Approves CABOMETYX(TM) (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Aug 2016
XALKORI(R) (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 30 Aug 2016
Portola Pharmaceuticals Announces Interim Results from Ongoing Phase 3b/4 ANNEXXA-4(TM) Study of Factor Xa Inhibitor Antidote AndexXa(TM) (andexanet alfa) in Patients with Acute Major Bleeding
Biopharmaceuticals
 HSMN NewsFeed - 19 Aug 2016
Portola Pharmaceuticals Announces Validation of Marketing Authorization Application (MAA) by European Medicines Agency (EMA) for IndexXa(TM) (andexanet alfa), a Factor Xa Inhibitor Antidote
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Aug 2016
Portola Pharmaceuticals Receives Complete Response Letter from FDA for Biologics License Application for AndexXa(TM) (andexanet alfa)
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Jul 2016
European Commission Approves Extended Indication For Amgen's Kyprolis(R) (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Jun 2016
Merck Receives CHMP Positive Opinion for KEYTRUDA(R) (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Jun 2016
Merck’s KEYTRUDA(R) (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 May 2016
Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting
Biopharmaceuticals
 HSMN NewsFeed - 2 Mar 2016
Firstkind Seeks Global Distribution Partners to Extend geko(TM) Device Roll-out
Devices Distribution
 HSMN NewsFeed - 21 Dec 2015
Oral REVLIMID(R) Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Nov 2015
Boston Scientific Receives FDA Approval And CE Mark For AngioJet(TM) ZelanteDVT(TM) Thrombectomy Catheter
Devices Interventional FDA Regulatory
 HSMN NewsFeed - 25 Nov 2015
Pfizer Receives European Approval to Expand Use of XALKORI(R) (crizotinib) to First-Line Treatment of Adults with ALK-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Nov 2015
European Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo(R) European Marketing Authorization Application
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Nov 2015
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Nov 2015
Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI(R) (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Aug 2015
NICE Recommends Once-daily Lixiana(R) (Edoxaban) for Preventing Stroke and Systemic Embolism in People with Non-valvular Atrial Fibrillation
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 6 May 2015
EMD Serono Initiates Co-Promotion of XALKORI(R) (crizotinib) with Pfizer in the United States
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 6 Apr 2015
FDA Expands Indication for EVARREST(R) Fibrin Sealant Patch
Devices Surgery FDA
 HSMN NewsFeed - 20 Feb 2015
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Nov 2014
Argon Medical's CLEANER XT(TM) and CLEANER 15(TM) Rotational Thrombectomy Systems Receive FDA Clearance for Mechanical Declotting and Infusion in the Peripheral Vasculature
Devices Interventional FDA
 HSMN NewsFeed - 10 Sep 2014
Mylan to Acquire U.S. Rights to Arixtra(R) (fondaparinux sodium) Injection from Aspen
Biopharmaceuticals Generics
 HSMN NewsFeed - 15 Jul 2014
Pradaxa(R) (dabigatran etexilate) Now Available in the UK for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and Prevention of Recurrence
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Jun 2014
Eliquis(R) (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 May 2014
EkoSonic(R) Endovascular System Receives FDA Clearance for the Treatment of Pulmonary Embolism in the USA
Devices Interventional FDA
 HSMN NewsFeed - 21 May 2014
Baxter Provides U.S. Regulatory Update on HyQvia, Its Investigational Subcutaneous Treatment for Primary Immunodeficiency
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 Mar 2014
Daiichi Sankyo Initiates Phase 3 ENSURE-AF Study, Investigating Once-Daily Edoxaban in Patients with Atrial Fibrillation Undergoing Cardioversion
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 24 Jan 2014
VENITI, Inc. Announces First Uses of Veniti Vici Venous Stent System
Devices Interventional
 HSMN NewsFeed - 20 Jan 2014
Pulmonary Embolism Trial Comparing Endovascular Ultrasound to Standard of Care Anticoagulation Published in the American Heart Association’s Journal, Circulation
Devices Interventional
 HSMN NewsFeed - 19 Dec 2013
Baxter Receives FDA Approval of FEIBA [Anti-Inhibitor Coagulant Complex] for Prophylactic Treatment of Hemophilia A&B Patients with Inhibitors
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Dec 2013
EMD Serono's Redesigned Fertility Pen Available for Distribution in US
Biopharmaceuticals Drug Delivery Product Launch
 HSMN NewsFeed - 26 Nov 2013
FDA Approves Varithena(TM) (Polidocanol Injectable Foam) for the Treatment of Patients with Varicose Veins
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Nov 2013
Auxilium Announces Results of the XIAFLEX(R) in Dupuytren's MULTICORD Contracture Trial
Biopharmaceuticals
 HSMN NewsFeed - 18 Nov 2013
BiO2 Medical Executes Q4 2013 Commercialization Strategy for the Angel(R) Catheter, Signing Distribution Partnership Agreements in Key European and Middle Eastern Geographies
Devices Distribution
 HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Sep 2013
Cimzia(R) (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Sep 2013
Bayer receives approval for Adempas(R) as first drug to treat rare heart and lung disease
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Aug 2013
FDA Accepts Boehringer Ingelheim's Supplemental New Drug Application for Use of Dabigatran Etexilate Mesylate in Deep Vein Thrombosis and Pulmonary Embolism
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Aug 2013
BiO2 Medical Executes Full Commercialization in the United Kingdom Partnering with United Drug Medical (UDM) as an Exclusive Distributor for the Angel(R) Catheter
Devices Interventional Distribution
 HSMN NewsFeed - 18 Jul 2013
Celgene Will Discontinue Phase III ORIGIN(R) Trial in Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2013
Oral Anti-Cancer Therapy Pomalidomide Celgene Receives Positive CHMP Opinion as Treatment for Patients with Relapsed and Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 May 2013
BiO2 Medical's IDE Application for the Angel(TM) Catheter Receives FDA Approval
Devices FDA
 HSMN NewsFeed - 10 Apr 2013
Kaleidoscope Medical Secures Series A Funding
Devices Venture Capital
 HSMN NewsFeed - 4 Apr 2013
Argon Medical Devices Announces The Launch Of OptionELITE Retrievable Vena Cava Filter And The Acquisition of Angiotech Interventional Business
Devices Interventional
 HSMN NewsFeed - 19 Feb 2013
Toshiba’s Advanced CT Helps Reduce Radiation Dose for Safer Exams
Devices Radiology
 HSMN NewsFeed - 5 Feb 2013
ZALTRAP(R) (ziv-aflibercept) Approved in the EU for Patients with Previously Treated Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Dec 2012
FDA Approves EVARREST(TM) Fibrin Sealant Patch
Devices Surgery FDA
 HSMN NewsFeed - 3 Dec 2012
Volcano Corporation Announces Agreement To Acquire Crux Biomedical
Devices Interventional Mergers & Acquisitions
 HSMN NewsFeed - 17 Sep 2012
Pfizer To Present New Data in Lung And Kidney Cancers at The European Society For Medical Oncology 2012 Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Sep 2012
BiO2 Medical Raises $12M in Series C Funding
Devices Venture Capital
 HSMN NewsFeed - 4 Sep 2012
Pfizer Receives EU Marketing Authorization for INLYTA(R) (Axitinib)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Jul 2012
FDA Clears First Ever Bi-directionally Retrievable Vena Cava Filter from Crux Biomedical
Devices Interventional FDA
 HSMN NewsFeed - 29 Jun 2012
Actelion Pharmaceuticals Announces U.S. Food and Drug Administration Approval of Supplemental New Drug Application for Second Generation VELETRI(R) (epoprostenol) for Injection
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Jun 2012
Baxter Announces FDA Approval for GAMMAGARD LIQUID as a Treatment for Multifocal Motor Neuropathy
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 5 Jun 2012
Former Pfizer Worldwide Business Development Director Joins Australian Drug Development Company Agenix
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 May 2012
EKOS Corporation Announces Two More Pulmonary Embolism Clinical Studies
Devices Drug Delivery
 HSMN NewsFeed - 27 Apr 2012
Baxter Presents Efficacy and Safety Data Evaluating GAMMAGARD LIQUID for Multifocal Motor Neuropathy at AAN Annual Meeting
Biopharmaceuticals Neurology
 HSMN NewsFeed - 27 Mar 2012
InterMune Appoints Mr. Jean-Jacques Bienaime and Dr. Frank Verwiel to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Mar 2012
CSL Behring Announces First Patient Treated in Phase III Study of Fibrinogen Concentrate (Human)(FCH) to Control Bleeding During Aortic Aneurysm Surgery
Biopharmaceuticals Surgery
 HSMN NewsFeed - 13 Dec 2011
Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery
Biopharmaceuticals
 HSMN NewsFeed - 9 Nov 2011
Merck Launches NEXPLANON(R) (etonogestrel implant) 68 mg in the United States – A Long-Acting Reversible Hormonal Contraceptive Effective For Up to Three Years
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 9 Nov 2011
FDA Accepts Genentech’s New Drug Application For Vismodegib in Advanced Form of Skin Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Sep 2011
Genentech Submits New Drug Application to FDA for Vismodegib for Rare Form of Advanced Skin Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Sep 2011
FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 25 Jul 2011
Baxter Announces FDA Approval of Subcutaneous Route of Administration for GAMMAGARD LIQUID for Patients with Primary Immunodeficiency
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Jul 2011
Merck Receives Approval to Market GARDASIL(R), ZOLINZA(R) and CUBICIN(R) in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 31 May 2011
Medical Compression Systems Receives FDA Clearance for New 'Prevention and Detection' Product
Devices FDA
 HSMN NewsFeed - 20 May 2011
ELIQUIS(R) (apixaban) Approved In Europe For Preventing Venous Thromboembolism After Elective Hip Or Knee Replacement
Biopharmaceuticals Surgery Orthopaedic
 HSMN NewsFeed - 22 Apr 2011
Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA(R) (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery
Biopharmaceuticals Surgery Regulatory
 HSMN NewsFeed - 15 Mar 2011
Argon Medical Devices Announces Exclusive License and Distribution Agreement for Option Retrievable Inferior Vena Cava Filter
Devices Distribution Licensing
 HSMN NewsFeed - 15 Feb 2011
Venous Health Systems Receives FDA Clearance to Commercialize Fully Portable Pneumatic Compression System to Treat Vascular Insufficiency
Devices FDA
 HSMN NewsFeed - 17 Jan 2011
EKOS Corporation Receives CE Mark to Treat Massive and Sub-Massive Pulmonary Embolism
Devices Regulatory
 HSMN NewsFeed - 22 Dec 2010
Newly Published Investigational Apixaban ADVANCE-3 Study Results Demonstrate Statistical Superiority to Enoxaparin with Comparable Rates of Bleeding in the Prevention of Venous Thromboembolism Following Total Hip Replacement Surgery
Biopharmaceuticals Orthopaedic Surgery
 HSMN NewsFeed - 4 Nov 2010
Covidien Receives FDA 510(k) Clearance for Kendall SCD(TM) Compression Comfort Sleeve and Kendall SCD(TM) 700 Series Controller
Devices FDA
 HSMN NewsFeed - 14 Oct 2010
Talecris Biotherapeutics Receives FDA Approval for Gamunex(R)-C
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Oct 2010
Covidien Demonstrates Breakthroughs in Minimally Invasive Surgery and Soft Tissue Repair at 2010 American College of Surgeons Clinical Congress (ACS)
Devices Surgery
 HSMN NewsFeed - 23 Sep 2010
Portola Pharmaceuticals Appoints Jean-Jacques Bienaime to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Aug 2010
Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study
Biopharmaceuticals
 HSMN NewsFeed - 20 Aug 2010
REVLIMID(R) Approved for Treatment of Deletion 5q Myelodysplastic Syndromes in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Jul 2010
Abraxis BioScience and Specialised Therapeutics Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Jul 2010
ABRAXANE(R) Approved for Marketing in Japan for Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Jul 2010
GTC Biotherapeutics Regains US Rights to ATryn(R) ; the First Recombinant Antithrombin Product Approved in the World
Biopharmaceuticals
 HSMN NewsFeed - 1 Jul 2010
FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Jun 2010
New ABRAXANE(R) Data Demonstrates Potential in Patients with Advanced and Malignant Melanoma, Among the Toughest Cancers to Treat
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2010
CoaguSense Receives FDA Clearance for the CoaguSense Blood Coagulation Testing System for Patient Home Use
Devices Diagnostics Monitoring FDA
 HSMN NewsFeed - 15 Apr 2010
Comparative Trial of Canyon's Iprivask(R) (Desirudin) with Standard of Care Shows Favorable Outcomes for Thrombosis Prophylaxis in Surgery Patients with HIT
Biopharmaceuticals
 HSMN NewsFeed - 17 Mar 2010
ABRAXANE Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Feb 2010
Instrumentation Laboratory Receives 510(K) Clearance From FDA and Canadian License for HemosIL(R) D-Dimer HS 500 Assay
Diagnostics FDA Regulatory
 HSMN NewsFeed - 18 Jan 2010
EKOS Corporation Announces Clinical Study for the Treatment of Pulmonary Embolism Using the EKOS EkoSonic(R) Endovascular Device
Devices Interventional
 HSMN NewsFeed - 23 Sep 2009
Cook Medical's Advanced NavAlign Delivery System for IVC Filters Adds Procedural Speed, Control and Accuracy
Devices
 HSMN NewsFeed - 20 Aug 2009
Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
Devices Interventional
 HSMN NewsFeed - 17 Aug 2009
Real-World Study Showed Cost Savings for VTE Prophylaxis with Enoxaparin Compared with Unfractionated Heparin (UFH)
Biopharmaceuticals
 HSMN NewsFeed - 3 Aug 2009
Results from a Phase 2 Study of ABRAXANE(R) In Combination With Carboplatin Show Clinical Activity in the First Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jun 2009
Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
Devices Interventional FDA
 HSMN NewsFeed - 20 Mar 2009
Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 11 Mar 2009
CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Feb 2009
Neuisys Announces FDA Clearance of NeuViz 16 Multi-Slice CT System
Devices Radiology FDA
 HSMN NewsFeed - 17 Jan 2009
CSL Behring Receives FDA Approval of RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Dec 2008
Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 25 Sep 2008
Recent Research Shows Significant Benefits in Acute Ischaemic Stroke With Actilyse(R) Beyond Currently Approved Three Hour Treatment Window
Biopharmaceuticals Neurology
 HSMN NewsFeed - 24 Sep 2008
ImaRx Therapeutics Divests Urokinase Franchise to Microbix Biosystems
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 24 Sep 2008
Nice Approves Pradaxa(R)*(Dabigatran Etexilate) - First New Oral Anticoagulant in the UK for Over 50 Years
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Aug 2008
Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use of HemosIL(R) D-Dimer Assay
Diagnostics FDA
 HSMN NewsFeed - 30 Jul 2008
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Rivaroxaban
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Jul 2008
Chest Physicians Now Suggest Early Intervention for Certain Blood Clots in DVT
Devices Interventional
 HSMN NewsFeed - 22 Jul 2008
EKOS(R) Introduces New EkoSonic(TM) Endovascular System With Rapid Pulse(TM) Modulation Technology - Four Times Faster Than Conventional Catheter-Directed Thrombolysis
Devices Interventional
 HSMN NewsFeed - 1 Jun 2008
Updated REVLIMID(R) Data Presented in Newly Diagnosed Multiple Myeloma Presented at the 2008 American Society of Clinical Oncology (ASCO) Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2008
Updated Data from Ongoing Phase 3 Trials Support the Continued Study of Vectibix(R) (panitumumab) in Combination with Standard Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2008
Rivaroxaban Superior to U.S.-Approved Dosing Regimen for Enoxaparin in Reducing Venous Blood Clots after Total Knee Replacement Surgery in Pivotal Phase III Trial
Biopharmaceuticals Orthopaedic Surgery
 HSMN NewsFeed - 13 May 2008
Siemens Introduces Dual Energy Applications for General Imaging
Devices Radiology
 HSMN NewsFeed - 14 Apr 2008
KV Begins Shipping Evamist(TM) to Wholesalers
Biopharmaceuticals
 HSMN NewsFeed - 27 Mar 2008
Novel Oral Anticoagulant Pradaxa(R) (dabigatran etexilate) Approved by the European Commission
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Mar 2008
Cook Medical Receives FDA 510(k) Clearance for Celect(TM) Vena Cava Filter and Gunther Tulip(TM) Vena Cava Filter Retrieval Set
Devices FDA
 HSMN NewsFeed - 13 Mar 2008
Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
Devices Licensing
 HSMN NewsFeed - 10 Mar 2008
Siemens Introduces New Dual Energy Applications to SOMATOM Definition
Devices Radiology
 HSMN NewsFeed - 25 Feb 2008
GTx's Toremifene Citrate 80 mg Meets Primary and Key Endpoints in Phase III Trial in Advanced Prostate Cancer Patients on Androgen Deprivation Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jan 2008
ImaRx Therapeutics Transitions Business Strategy
Biopharmaceuticals
 HSMN NewsFeed - 28 Jan 2008
Clexane(R)/Lovenox(R) Approved in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 Jan 2008
ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Jan 2008
Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Jan 2008
ImaRx and Microbix Sign Letter of Intent to Manufacture and Further Develop the FDA-Approved Clot-Dissolving Drug, Abbokinase(R)
Biopharmaceuticals
 HSMN NewsFeed - 4 Jan 2008
ImaRx Provides Update on TUCSON Phase I/II Clinical Trial in Acute Ischemic Stroke
Biopharmaceuticals Neurology
 HSMN NewsFeed - 21 Dec 2007
New Drug Application for Tolvaptan, Otsuka's Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 9 Dec 2007
REVLIMID(R) (Lenalidomide) Plus Low-Dose Dexamethasone Achieves Unprecedented Survival Rate in ECOG Phase III Trial in Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2007
Pivotal Phase III Data Showed Rivaroxaban Was Statistically Superior to Enoxaparin in Preventing Venous Thromboembolism (VTE) in Patients Following Hip Replacement Surgery
 HSMN NewsFeed - 20 Nov 2007
DJO Incorporated Closes Merger Transaction with ReAble Therapeutics
Devices Orthopaedic Mergers & Acquisitions
 HSMN NewsFeed - 6 Nov 2007
DJO Incorporated Announces Stockholder Approval of Merger with ReAble Therapeutics
Devices Mergers & Acquisitions
 HSMN NewsFeed - 5 Nov 2007
ImaRx Therapeutics and Philips to Collaborate on Potential Treatment for Ischemic Stroke Using Microbubbles and Ultrasound
Devices Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Oct 2007
Gilead Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 9 Oct 2007
Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use for HemosIL(R) D-Dimer HS Assay
Diagnostics FDA
 HSMN NewsFeed - 4 Oct 2007
Acorn Acquisition Corp Announces Definitive Agreement to Acquire Lumen Medical Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 3 Oct 2007
Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter
Devices
 HSMN NewsFeed - 2 Oct 2007
Duramed Launches New Indication for ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) at North American Menopause Society Annual Meeting
Biopharmaceuticals
 HSMN NewsFeed - 1 Oct 2007
bioMerieux Launches VIDAS(R) NT-proBNP, an Aid for Diagnosis and Prognosis of Heart Failure
Diagnostics Cardiology Regulatory
 HSMN NewsFeed - 20 Sep 2007
ImaRx Therapeutics Names Richard L. Love as Chairman and Announces Management Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Sep 2007
B. Braun Medical Inc. Issues Nationwide Recall of Normal Saline Flush Syringes with Lot Numbers Ending in "SFR"
Devices Product Recall
 HSMN NewsFeed - 6 Sep 2007
Aranesp(R) Study Showing No Negative Impact on Survival in SCLC Presented at World Conference on Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Sep 2007
Oral Cancer Drug REVLIMID(R) Receives Swissmedic Approval in Switzerland for Treatment of Multiple Myeloma
Biopharmaceuticals Regulatory Oncology
 HSMN NewsFeed - 28 Aug 2007
ImaRx Therapeutics Receives DSMB Approval to Proceed with Second Dose Cohort in TUCSON Trial of SonoLysis(TM) + tPA Therapy in Acute Ischemic Stroke
Biopharmaceuticals Neurology
 HSMN NewsFeed - 21 Aug 2007
DJO Incorporated Receives FDA Market Approval for Enhanced Patient Features for Its Line of OL1000 and SpinaLogic(R) Bone Growth Stimulation Products
Devices Orthopaedic FDA
 HSMN NewsFeed - 16 Aug 2007
Covalon Advances its Antimicrobial Coating to be Non-Blood-Clotting for Venous Access Catheters and Devices
Devices
 HSMN NewsFeed - 30 Jul 2007
Cook Medical Receives FDA Clearance for Celect(TM) Vena Cava Filter
Devices Interventional FDA
 HSMN NewsFeed - 30 Jul 2007
VIVUS Receives FDA Approval of Evamist NDA
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 20 Jul 2007
Journal of Clinical Oncology Publishes Data on ZOLINZA(TM) (vorinostat), Merck's Treatment for Advanced Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jul 2007
Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Biopharmaceuticals
 HSMN NewsFeed - 8 Jul 2007
New Study Shows That Extending Prophylaxis With Clexane(R) / Lovenox(R) (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Biopharmaceuticals
 HSMN NewsFeed - 6 Jul 2007
Dade Behring Introduces Innovance(TM) D-DIMER Test
Diagnostics
 HSMN NewsFeed - 3 Jul 2007
Bracco International and ImaRx Therapeutics Enter into Strategic Licensing Agreement
Diagnostics Radiology Licensing
 HSMN NewsFeed - 19 Jun 2007
REVLIMID(R) Granted Full Marketing Authorization for Treatment of Multiple Myeloma in the European Union
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Jun 2007
Bradley Pharmaceuticals Announces Launch of Elestrin(TM)
Biopharmaceuticals
 HSMN NewsFeed - 4 Jun 2007
Pharmion Announces French ATU Granted for Use of Thalidomide for Elderly Patients With Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Jun 2007
Xeloda(R) Plus Avastin(R) Combination Delays Disease Progression in Women with Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 May 2007
FDA Approves Lovenox(R) (Enoxaparin Sodium Injection) for the Most Severe Type of Heart Attack
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 15 May 2007
SWOG Phase III Newly Diagnosed Multiple Myeloma Trial (S0232) Closed and Patients Given Choice to Switch to REVLIMID(R) Plus Dexamethasone
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 May 2007
Rex Medical Announces the Successful Retrieval of the Option(TM) Vena Cava Filter up to Day 225 in an International Clinical Study
Devices
 HSMN NewsFeed - 2 May 2007
FDA Approves FRAGMIN(R) as First Low-Molecular-Weight Heparin for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients with Cancer
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Apr 2007
Duramed's ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) Tablets Receives Two New FDA Approvals
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Apr 2007
Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds
Biopharmaceuticals
 HSMN NewsFeed - 20 Apr 2007
The Lancet Publishes PREVAIL Study Results Showing Lovenox(R) Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
Biopharmaceuticals
 HSMN NewsFeed - 4 Apr 2007
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports LENALIDOMIDE Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Mar 2007
Breakthrough Clinical Results Reveal Extended Retrieval Times for Cook Medical's Gunther Tulip(TM) Vena Cava Filter
Devices Interventional
 HSMN NewsFeed - 25 Mar 2007
Data Shows That Omission of Venous Thromboembolism (VTE) Prophylaxis in Hospitalized Medical Patients Is Frequent and Leads to Higher Risk of Deep-Vein Thrombosis (DVT)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 23 Mar 2007
Oral Cancer Drug REVLIMID(R) Receives Positive Opinion for Treatment of Multiple Myeloma From European Medicines Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Mar 2007
Amgen Discontinues Vectibix(TM) Treatment in Pacce Trial Evaluating Vectibix(Tm) as Part of Triple Combination Regimen
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Mar 2007
Anthera Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board for Respiratory and Acute Care Programs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Mar 2007
EMEA Accepts for Review Thalidomide Pharmion(R) Marketing Authorization Application for Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Feb 2007
Rex Medical Announces the Successful Retrieval of the Option(TM) Vena Cava Filter from a Femoral Approach In Vivo
Devices Interventional
 HSMN NewsFeed - 7 Feb 2007
FDA Grants Priority Review to Lovenox(R) (Enoxaparin Sodium Injection) Supplemental New Drug Application (sNDA) for Acute Heart Attack
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 1 Feb 2007
Crux Biomedical Announces Successful Completion of Trials for a New Retrievable Inferior Vena Cava (IVC) Filter
Devices
 HSMN NewsFeed - 1 Feb 2007
Sanofi-aventis Applauds New National Standards for Prophylaxis of Venous Thromboembolism in Surgical Patients
Biopharmaceuticals
 HSMN NewsFeed - 23 Jan 2007
Pharmion Submits European Marketing Authorization Application for Thalidomide Pharmion(R) for Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Jan 2007
Rex Medical Announces the Successful Clinical Retrieval of the Option(TM) Vena Cava Filter Up To Day 107 in an International Clinical Study
Devices
 HSMN NewsFeed - 15 Dec 2006
Xeloda(R) Plus Avastin(R) Combination May Produce Clinical Benefit in Patients with Advanced Breast Cancer
Biopharmaceuticaals Oncology
 HSMN NewsFeed - 13 Dec 2006
New England Journal of Medicine Publishes Data from Pivotal Study of Avastin Plus Chemotherapy in Most Common Type of Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Dec 2006
Possis Invests in IVC Filter Company
Devices
 HSMN NewsFeed - 12 Dec 2006
Rex Medical Announces the Successful Clinical Retrieval of the Option(TM) Vena Cava Filter in an International Clinical Study
Devices Interventional
 HSMN NewsFeed - 12 Dec 2006
New Study Shows Clexane(R) / Lovenox(R) (Enoxaparin Sodium Injection) is More Effective Than Unfractionated Heparin (UFH) for Preventing the Risk of Venous Thromboembolism (VTE) in Patients With Acute Ischemic Stroke
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2006
New Study Shows Lovenox(R) (Enoxaparin Sodium Injection) Is More Effective Than Unfractionated Heparin (UFH) for Lowering the Risk of Venous Thromboembolism (VTE) in Patients With Acute Ischemic Stroke
Biopharmaceuticals
 HSMN NewsFeed - 11 Dec 2006
Positive Phase 3 Results for New Fixed Oral Dose Anticoagulant Presented at 48th Annual Meeting of the American Society of Hematology
Biopharmaceuticals
 HSMN NewsFeed - 8 Dec 2006
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Nov 2006
FDA Clears Possis AngioJet(R) System for Blood Clot Removal in Veins
Devices FDA Interventional
 HSMN NewsFeed - 6 Nov 2006
New Low Profile Optional Vena Cava Filter Receives Conditional FDA Approval to Begin U.S. Clinical Trial
Devices FDA
 HSMN NewsFeed - 9 Oct 2006
FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Oct 2006
FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Oct 2006
Rex Medical Announces the Successful Clinical Implantation of the Option(TM) Retrievable Vena Cava Filter in First Human Use
Devices
 HSMN NewsFeed - 2 Oct 2006
Updated REVLIMID(R) (lenalidomide) Clinical Results Presented at the 3rd International Conference on Innovative Therapies for Lymphoid Malignancies
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Sep 2006
British Journal of Haematology Publishes Thrombosis Findings From ASCENT Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jun 2006
REVLIMID(R) in Combination With Dexamethasone sNDA Granted Approval By FDA for Treatment of Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 May 2006
dj Orthopedics Announces Corporate Name Change to DJO Incorporated to Reflect Growth in Business
Devices Orthopaedic
 HSMN NewsFeed - 12 May 2006
Surgical Patch Provides Break-Through in Lung Surgery
Devices Surgery
 HSMN NewsFeed - 8 May 2006
ImaRx Acquires Abbokinase
Biopharmaceuticals Acquisitions
Return to NewsFeed  

 Additional items found! 95

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 95 additional stories matching:
Pulmonary Embolism
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.